Gate App Options Now Live! Test and Win Big
📅 Event Period: September 30, 2025 – October 17, 2025
- Submit valid feedback to receive 10–100 USDT.
- Complete at least 10,000 USDT in cumulative options trading volume to participate.
👉 Register now :https://www.gate.com/campaigns/2063
Details: https://www.gate.com/zh-tw/announcements/article/47455
BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.
Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.